Protagonist closes tranche in $18M round; Teva pays a $15M milestone;

@FierceBiotech: Party time at Array as Novartis bows out of PhIII binimetinib cancer program. Report | Follow @FierceBiotech

@JohnCFierce: College students with big ideas can shoot for some seed money from Xfund. Harvard-based--$100M. More from the WSJ | Follow @JohnCFierce

@DamianFierce: Blincyto, which sounds like it's related to the cells of blintzes, is the name of Amgen's new cancer drug. More | Follow @DamianFierce

> Milpitas, CA-based Protagonist Therapeutics has closed on the second tranche of its $18 million B round. The biotech is using the money to advance toward the clinic with PTG-100, an alpha-4-beta-7 integrin specific antagonist peptide for inflammatory bowel disease. Release

> CTI BioPharma received a $15 million milestone payment from Teva ($TEVA) related to the achievement of sales milestones for Trisenox (arsenic trioxide). Release

Medical Device News

@FierceMedDev: ICYMI: Illumina and Sequenom lay ongoing prenatal diagnostic patent feud to rest. Article | Follow @FierceMedDev

@EmilyWFierce: Britain's BTG scoops up pulmonology outfit PneumRx for up to $475M. Story | Follow @EmilyWFierce

> Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition. Item

> Hospital requires use of wireless, wearable sensors to prevent bedsores. News

> HeartFlow's noninvasive test for coronary artery disease cleared by FDA. More

Pharma News

@FiercePharma: Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. FierceVaccines article | Follow @FiercePharma

@EricPFierce: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. News | Follow @EricPFierce

@CarlyHFierce: Universal flu vaccine developer BiondVax mulling IPO. Globes | Follow @CarlyHFierce

> Incyte's Jakafi gets a boost with FDA nod for bone marrow disease. More

> Ranbaxy now faces product bans in Europe. Story

> Bayer and J&J push back against consolidation of Xarelto suits. News

Vaccines News

> Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. Article

> Universal flu vax developer BiondVax mulling IPO: Globes. Item

> GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI. Report

> Merck, NewLink Ebola vaccine trial shows no serious side effects so far. Story

> Novartis' Fluad off the hook in Italy following 19 deaths. Article

Pharma Manufacturing News

> EMA clears Novartis Fluad in deaths in Italy. Item

> Johnson Matthey buys former Glaxo facility in Scotland. More

> Strides Arcolab begins construction of $60M Malaysia facility. Report

> Some Indian drugmakers routinely toss out bad test results: Bloomberg. Story

> Germany, EU, join U.S. in banning India-made Ranbaxy products. Article

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.